Growth inhibitory effects and mechanisms of lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinase, in gastric cell lines

被引：0
|
作者：
Kim, J. W. [1 ]
Im, S. A. [2 ]
Kim, H. P. [3 ]
Oh, D. Y. [2 ]
Kim, T. Y. [2 ]
Bang, Y. J. [2 ]
机构：
[1] Seoul Natl Univ, Seoul, South Korea
[2] Seoul Natl Univ, Internal Med & Canc Res Inst, Seoul, South Korea
[3] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71012-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3509
引用
收藏
页码：262 / 262
页数：1
相关论文
共 50 条
  • [1] Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts
    Mellinghoff, IK
    Tran, C
    Sawyers, CL
    CANCER RESEARCH, 2002, 62 (18) : 5254 - 5259
  • [2] Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor
    Lackey, Karen E.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (05) : 435 - 460
  • [3] Acquired resistance to a dual erbB1 and erbB2 kinase inhibitors
    Bacus, Sarah S.
    Hill, Jason
    Spector, Neil
    CANCER RESEARCH, 2006, 66 (08)
  • [4] Gw572016, a dual tyrosine kinase inhibitor, blocks activation of Erbb1 and Erbb2 in a bladder cancer cell line
    McHugh, LA
    Griffiths, TR
    Colquhoun, AJ
    Kriajevska, M
    Mellon, JK
    JOURNAL OF UROLOGY, 2004, 171 (04): : 188 - 188
  • [5] Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
    Spector, NL
    Xia, WL
    Burris, H
    Hurwitz, H
    Dees, EC
    Dowlati, A
    O'Neil, B
    Overmoyer, B
    Marcom, PK
    Blackwell, KL
    Smith, DA
    Koch, KM
    Stead, A
    Mangum, S
    Ellis, MJ
    Liu, LH
    Man, AK
    Bremer, TM
    Harris, J
    Bacus, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2502 - 2512
  • [6] Dual targeting of ErbB1 and ErbB2 enhances response to chemotherapy in ErbB2 overexpressing breast cancer cell lines.
    O'Donovan, N.
    Clynes, M.
    Crown, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S105 - S105
  • [7] Dual ErbB1/ErbB2 tyrosine kinase inhibition - a potential adjunct to systemic chemotherapy in bladder cancer
    McHugh, LA
    Griffiths, TRL
    Kriajevska, M
    Mellon, JK
    BJU INTERNATIONAL, 2005, 95 : 64 - 65
  • [8] Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors
    Kawada, Kenji
    Murakami, Koji
    Sato, Takashi
    Kojima, Yoshiki
    Ebi, Hiromichi
    Mukai, Hirofumi
    Tahara, Makoto
    Shimokata, Kaoru
    Minami, Hironobu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (01) : 44 - 48
  • [9] In vivo antitumor efficacy of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor
    Iwahara, A.
    Tamura, T.
    Takagi, S.
    Kamiguchi, H.
    Yusa, T.
    Ohta, Y.
    EJC SUPPLEMENTS, 2008, 6 (12): : 99 - 100
  • [10] Lapatinib (GW572016): a novel approach to inhibit ErbB1/ErbB2
    Stein, SH
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 697 - 697
12345